The European Union granted approval for Enhertu, a drug co-developed by AstraZeneca and Daiichi Sankyo.
2 reports, 1 independent
Updated Jul 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Union granted approval for Enhertu, a drug co-developed by AstraZeneca and Daiichi Sankyo.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
company in Osaka, Japan
Nothing else this week.
-
Daiichi Sankyo
Japanese pharmaceutical company
Related events
- Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.
- Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.
- Zevra Therapeutics and Daiichi Sankyo are involved in the competitive healthcare investment space, with Zevra developing products for serious medical conditions.